+94.7%
NEM vs MRNA
-27.3%
+121.9%
-62.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.4% | -2.2% | -3.2% | -5.2% |
| 7D | -16.3% | -12.7% | -3.6% | -15.6% |
| 30D | -19.2% | -20.7% | +1.5% | -18.0% |
| 3M | -25.7% | +46.3% | -71.9% | -27.7% |
| 6M | -11.4% | +305.2% | -316.7% | -23.8% |
| YTD | -4.6% | +561.2% | -565.8% | -20.9% |
| 1Y | +16.5% | +772.1% | -755.5% | -5.2% |
| 3Y | +174.4% | +147.0% | +27.4% | +132.6% |
| All | +94.7% | -27.3% | +121.9% | +75.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling